Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of DuoChol Oral Cholera Vaccine in Healthy Participants in Sweden
NCT07270796Phase 1Not yet recruiting
- Sponsor
- International Vaccine Institute
- Start
- Jan 2027
- Primary completion
- Jul 2027
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of DuoChol in cholera (2 arms), sponsored by International Vaccine Institute. Primary endpoint: Safety of each investigational product dose at 6 weeks. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
DuoChol
03
Conditions
cholera
Beyond the preview
Go deeper on NCT07270796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07270796.